评估SF3B1表达作为III期三阴性乳腺癌新辅助化疗反应的预后标志物
Assessment of SF3B1 Expression as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Stage III Triple-Negative Breast Cancer.
作者信息
Wihandani Desak Made, Adiputra Putu Anda Tusta, Wiguna Gede Wikania Wira, Saputra Putu Gede Septiawan, Yani Made Violin Weda, Anjani Ida Ayu Widya, Putra Wayan Ardyan Sudartha, Supadmanaba Gede Putu
机构信息
Biochemistry Department, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia.
Surgical Oncology Subdivision, Department of Surgery, Faculty of Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia.
出版信息
Rep Biochem Mol Biol. 2025 Jan;13(4):570-578. doi: 10.61186/rbmb.13.4.570.
BACKGROUND
SF3B1 is a splicing factor that plays a crucial role in cancer progression and is commonly found in various types of solid cancers. However, the reports regarding the clinical implications of SF3B1 in terms of therapy response, survival, and its relationship with patients' clinicopathological features are still limited. This study aimed to assess SF3B1 expression for neoadjuvant chemotherapy response in stage III triple-negative breast cancer.
METHODS
This case-control study was conducted at Prof. Dr. I.G.N.G. Ngoerah General Hospital from March to October 2021. Stage III TNBC breast cancer patients who received neoadjuvant chemotherapy were included. Variables assessed included SF3B1 expression, NAC response, and various histological and clinical parameters. Immunohistochemistry (IHC) for SF3B1 expression was performed using the avidin-biotin method. Data analysis involved univariate, bivariate (chi-square), and multivariate (logistic regression) methods using SPSS, with significance set at p ≤ 0.05.
RESULTS
Analysis showed that high Ki-67, tumor-infiltrating lymphocytes (TILs), and SF3B1 status significantly increased the risk of chemoresistance in TNBC breast cancer (OR=6.4, 95%CI=1.20-34.19, p-value=0.017; OR=4.8, 95%CI=1.05-21.75, p-value=0.031; OR=13.5, 95%CI=1.56-116.24, p-value=0.008, respectively) No significant relationships were found with age, grading, or menopausal status. Multivariate analysis confirmed these variables independently influenced chemoresistance, with aOR=14.4, 95%CI=1.80-115.73 for Ki-67 (p-value=0.012), aOR=6.7, 95%CI=1.12-40.46 for TIL (p-value=0.037), and aOR=13.714, 95%CI=1.56-116.24 for SF3B1 (p-value=0.018).
CONCLUSIONS
High SF3B1 expression, alongside high Ki-67 and TIL levels, is potentially a prognostic marker for chemoresistance in stage III TNBC. These findings suggest that targeting SF3B1 could offer a novel therapeutic approach in TNBC patients.
背景
SF3B1是一种剪接因子，在癌症进展中起关键作用，常见于各种实体癌中。然而，关于SF3B1在治疗反应、生存方面的临床意义及其与患者临床病理特征关系的报道仍然有限。本研究旨在评估III期三阴性乳腺癌中SF3B1表达对新辅助化疗反应的影响。
方法
本病例对照研究于2021年3月至10月在伊.G.N.G.恩戈拉教授综合医院进行。纳入接受新辅助化疗的III期三阴乳腺癌患者。评估的变量包括SF3B1表达、新辅助化疗反应以及各种组织学和临床参数。采用抗生物素蛋白-生物素法进行SF3B1表达的免疫组织化学（IHC）检测。数据分析采用SPSS进行单变量、双变量（卡方检验）和多变量（逻辑回归）分析，显著性设定为p≤0.05。
结果
分析表明，高Ki-67、肿瘤浸润淋巴细胞（TILs）和SF3B1状态显著增加三阴乳腺癌化疗耐药风险（OR分别为6.4，95%CI=1.20-34.19，p值=0.017；OR=4.8，95%CI=1.05-21.75，p值=0.031；OR=13.5，95%CI=1.56-116.24，p值=0.008）。未发现与年龄、分级或绝经状态有显著关系。多变量分析证实这些变量独立影响化疗耐药，Ki-67的校正OR=14.4，95%CI=1.80-115.73（p值=0.012），TIL的校正OR=6.7，95%CI=1.12-40.46（p值=0.037），SF3B1的校正OR=13.714，95%CI=1.56-116.24（p值=0.018）。
结论
高SF3B1表达以及高Ki-67和TIL水平可能是III期三阴乳腺癌化疗耐药的预后标志物。这些发现表明，靶向SF3B1可能为三阴乳腺癌患者提供一种新的治疗方法。
Zotero 插件